Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gerresheimer AG's accounts receivables for the quarter that ended in Nov. 2025 was CHF308 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Gerresheimer AG's Days Sales Outstanding for the quarter that ended in Nov. 2025 was 47.30.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gerresheimer AG's Net-Net Working Capital per share for the quarter that ended in Nov. 2025 was CHF-73.95.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Gerresheimer AG's Days Sales Outstanding for the quarter that ended in Nov. 2025 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gerresheimer AG's accounts receivable are only considered to be worth 75% of book value:
Gerresheimer AG's Net-Net Working Capital Per Share for the quarter that ended in Nov. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Gerresheimer AG Accounts Receivable Related Terms
Gerresheimer AG Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Gerresheimer AG's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of CHF308 Mil mean?
Gerresheimer AG (XSWX:GXI) has a Accounts Receivable of CHF308 Mil as of Nov. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Gerresheimer AG and its competitors.
Is Gerresheimer AG's Accounts Receivable too high?
Gerresheimer AG's current Accounts Receivable is CHF308 Mil. Overall, Gerresheimer AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's Accounts Receivable compare to ISRG and BDX?
Gerresheimer AG's Accounts Receivable of CHF308 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Gerresheimer AG and its competitors. Gerresheimer AG's current Accounts Receivable is CHF308 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Gerresheimer AG (XSWX:GXI) has a current Accounts Receivable of CHF308 Mil. The stock's GF Value™ is CHF90.02, compared to a current price of CHF25.84 — trading 71.3% below its estimated fair value. The current Accounts Receivable is CHF308 Mil. Gerresheimer AG's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Gerresheimer AG (XSWX:GXI), the current Accounts Receivable is CHF308 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (XSWX:GXI) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of CHF25.84 is trading 71.3% below its estimated GF Value™ of CHF90.02.
Key valuation signals for XSWX:GXI:
Accounts Receivable: CHF308 Mil
GF Value™: CHF90.02 vs. price of CHF25.84 (71.3% below fair value)
No single metric tells the full story. See the XSWX:GXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
68GF Score
Get the complete analysis for XSWX:GXI
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GXI has been successfully added to your 
